LPA and atherosclerosis: Thus, screening for genetic factors of Lp(a) is expected to have added value and proves to be cost-effective in primary prevention, whereas the monitoring of serum Lp(a) levels could improve the prediction of the clinical risk of atherosclerotic damage in patients with ASCVD [36,37].